Return to Today's science sparks archives

Information Click the tweet icon above each article title to share it on Twitter.

2021-11-26

Fig 3. Spectrum of somatic alterations associated with response to immune-checkpoint blockade (ICB)

Fig 3. Spectrum of somatic alterations associated with response to immune-checkpoint blockade (ICB)
  • Attalla K, DiNatale RG, Rappold PM, Fong CJ, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee CH, Carlo MI, Durack JC, Solomon SB, Reuter VE, Russo P, Chan TA, Motzer RJ, Schultz ND, Reznik E, Voss MH, Hakimi AA

  • Clin Cancer Res. 2021 Oct 15;27(20):5595-5606. doi: 10.1158/1078-0432.CCR-20-4058. Epub 2021 Jul 14.

2021-11-24

Fig 1. A) Trainee reported experience (in numbers of cases) with the treatment of individual hematologic malignancies diagnoses and specialized radiation therapy techniques. B) Trainee reported comfort with various aspects of hematologic malignancies patient care

Fig 1. A) Trainee reported experience (in numbers of cases) with the treatment of individual hematologic malignancies diagnoses and specialized radiation therapy techniques. B) Trainee reported comfort with various aspects of hematologic malignancies patient care
  • Kahn JM, Yang JC, Yahalom J, Dabaja BS, Vapiwala N, Hoppe BS, Tseng YD, Pinnix CC, Parikh RR, Sim AJ, Plastaras JP, Gunther JR

  • J Cancer Educ. 2021 Oct 2. pii: 10.1007/s13187-021-02098-9. doi: 10.1007/s13187-021-02098-9.
Open Access button

2021-11-23

Fig. 5: Dispensability of germline pathogenicity in tumorigenesis.

Fig. 5: Dispensability of germline pathogenicity in tumorigenesis.
  • Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, Jayakumaran G, Prasad M, Hwee J, Sumer SO, de Bruijn I, Li X, Gao J, Schultz N, Cambria R, Galle J, Mukherjee S, Vijai J, Cadoo KA, Carlo MI, Walsh MF, Mandelker D, Ceyhan-Birsoy O, Shia J, Zehir A, Ladanyi M, Hyman DM, Zhang L, Offit K, Robson ME, Solit DB, Stadler ZK, Berger MF, Taylor BS

  • Nat Genet. 2021 Nov;53(11):1577-1585. doi: 10.1038/s41588-021-00949-1. Epub 2021 Nov 5.

2021-11-22

Visual Abstract.

Visual Abstract.
  • Imber BS, Chau KW, Lee J, Lee J, Casey DL, Yang JC, Wijentunga NA, Shepherd A, Hajj C, Qi S, Chelius MR, Hamlin PA, Palomba ML, Joffe E, Zhang Z, Zelenetz AD, Salles GA, Yahalom J

  • Blood Adv. 2021 Oct 26;5(20):4185-4197. doi: 10.1182/bloodadvances.2021004939.
Open Access button

2021-11-19

Graphical Abstract.

Graphical Abstract.
  • Chan JM, Quintanal-Villalonga A, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM

  • Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14.
Open Access button

2021-11-18

Fig. 3: The tumor–microenvironment interface is composed of specialized tumor and muscle cells.

Fig. 3: The tumor–microenvironment interface is composed of specialized tumor and muscle cells.
  • Hunter MV, Moncada R, Weiss JM, Yanai I, White RM

  • Nat Commun. 2021 Nov 1;12(1):6278. doi: 10.1038/s41467-021-26614-z.
Open Access button

2021-11-17

Fig. 6. Sankey diagram shows management decisions before (left) and after (right) 18F-FDG-PET and PET/CT in patients with cancer of unknown primary.

Fig. 6. Sankey diagram shows management decisions before (left) and after (right) 18F-FDG-PET and PET/CT in patients with cancer of unknown primary.
  • Woo S, Becker AS, Do RKG, Schoder H, Hricak H, Alberto Vargas H

  • Eur J Cancer. 2021 Nov 2;159:60-77. doi: 10.1016/j.ejca.2021.09.031.

2021-11-16

Graphical Abstract

Graphical Abstract
  • Kruse ML, Patel M, McManus J, Chung YM, Li X, Wei W, Bazeley PS, Nakamura F, Hardaway A, Downs E, Chandarlapaty S, Thomas M, Moore HC, Budd GT, Tang WHW, Hazen SL, Bernstein A, Nik-Zainal S, Abraham J, Sharifi N

  • JCI Insight. 2021 Oct 22;6(20). pii: e150403. doi: 10.1172/jci.insight.150403.
Open Access button

2021-11-15

Figure 2. Timeline of Important Dates.

Figure 2. Timeline of Important Dates.
  • Wijetunga NA, Imber BS, Caravelli JF, Mikhaeel NG, Yahalom J

  • Br J Radiol. 2021 Nov 1;94(1127):20210285. doi: 10.1259/bjr.20210285. Epub 2021 Jul 8.

2021-11-12

Figure 3. Patient assessment of the telemedicine on-treatment management visit.

Figure 3. Patient assessment of the telemedicine on-treatment management visit.
  • Shaverdian N, Gillespie EF, Cha E, Kim SY, Benvengo S, Chino F, Kang JJ, Li Y, Atkinson TM, Lee N, Washington CM, Cahlon O, Gomez DR

  • J Natl Compr Canc Netw. 2021 Jan 4:1-7. doi: 10.6004/jnccn.2020.7687.
Open Access button

2021-11-11

Fig. 3: Mitochondrial GSH import is essential for cell proliferation.

Fig. 3: Mitochondrial GSH import is essential for cell proliferation.
  • Wang Y, Yen FS, Zhu XG, Timson RC, Weber R, Xing C, Liu Y, Allwein B, Luo H, Yeh HW, Heissel S, Unlu G, Gamazon ER, Kharas MG, Hite R, Birsoy K

  • Nature. 2021 Nov;599(7883):136-140. doi: 10.1038/s41586-021-04025-w. Epub 2021 Oct 27.
Open Access button

2021-11-10

Abstract.

Abstract.
  • Ginsberg SD, Joshi S, Sharma S, Guzman G, Wang T, Arancio O, Chiosis G

  • J Neurochem. 2021 Oct 17. doi: 10.1111/jnc.15525.
Open Access button

2021-11-09

Figure 3 Overall survival and progression-free survival in resected patients (A) and unresected patients (B).

Figure 3 Overall survival and progression-free survival in resected patients (A) and unresected patients (B).
  • McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR

  • J Surg Oncol. 2021 Oct 31. doi: 10.1002/jso.26735.

2021-11-08

Graphical Abstract

Graphical Abstract
  • Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD

  • JCI Insight. 2021 Oct 22;6(20). pii: 151035. doi: 10.1172/jci.insight.151035.
Open Access button

2021-11-05

Fig. 1: Genomic landscape of RAD51B-associated cancers.

Fig. 1: Genomic landscape of RAD51B-associated cancers.
  • Setton J, Selenica P, Mukherjee S, Shah R, Pecorari I, McMillan B, Pei IX, Kemel Y, Ceyhan-Birsoy O, Sheehan M, Tkachuk K, Brown DN, Zhang L, Cadoo K, Powell S, Weigelt B, Robson M, Riaz N, Offit K, Reis-Filho JS, Mandelker D

  • NPJ Breast Cancer. 2021 Oct 11;7(1):135. doi: 10.1038/s41523-021-00339-0.
Open Access button

2021-11-04

Figure 3. TAM and T cell phenotypes associated with response to optimized therapy regimen.

Figure 3. TAM and T cell phenotypes associated with response to optimized therapy regimen.
  • Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS

  • Cancer Cell. 2021 Oct 11;39(10):1375-1387.e6. doi: 10.1016/j.ccell.2021.07.023. Epub 2021 Aug 19.
Open Access button

2021-11-03

Fig 1. Model of metabolic regulation of tumor immunogenicity: oncogenic-driven metabolic rewiring required for cancer cell growth can promote tumor immunogenicity.

Fig 1. Model of metabolic regulation of tumor immunogenicity: oncogenic-driven metabolic rewiring required for cancer cell growth can promote tumor immunogenicity.
  • Somarribas Patterson LF, Vardhana SA

  • Trends Immunol. 2021 Oct 2. pii: S1471-4906(21)00178-2. doi: 10.1016/j.it.2021.09.002.

2021-11-02

Fig. 1: Immune cell atlas of the LR-CHL microenvironment at single-cell resolution.

Fig. 1: Immune cell atlas of the LR-CHL microenvironment at single-cell resolution.
  • Aoki T, Chong LC, Takata K, Milne K, Marshall A, Chavez EA, Miyata-Takata T, Ben-Neriah S, Unrau D, Telenius A, Boyle M, Weng AP, Savage KJ, Scott DW, Farinha P, Shah SP, Nelson BH, Steidl C

  • Proc Natl Acad Sci U S A. 2021 Oct 12;118(41). pii: 2105822118. doi: 10.1073/pnas.2105822118.
Open Access button

2021-11-01

Fig. 1. Maximal response to therapy by mutation status in patients with NSCLC.

Fig. 1. Maximal response to therapy by mutation status in patients with NSCLC.
  • Gutierrez M, Guo R, Giaccone G, Liu SV, Hao Z, Hilton C, Hinson JM Jr, Kris MG, Orlemans EO, Drilon A

  • Lung Cancer. 2021 Oct 8;162:23-28. doi: 10.1016/j.lungcan.2021.10.001.

2021-10-29

Fig. 2. Magnetic resonance imaging (MRI) of histiocytoses of the nervous system.

Fig. 2. Magnetic resonance imaging (MRI) of histiocytoses of the nervous system.
  • Cohen Aubart F, Idbaih A, Emile JF, Amoura Z, Abdel-Wahab O, Durham BH, Haroche J, Diamond EL

  • Neuro Oncol. 2021 Sep 1;23(9):1433-1446. doi: 10.1093/neuonc/noab107.
Open Access button

2021-10-28

Fig. 3. Absolute contralateral breast cancer risk by PRS percentiles per age category of the first breast cancer diagnosis for BRCA1 and BRCA2 heterozygotes.

Fig. 3. Absolute contralateral breast cancer risk by PRS percentiles per age category of the first breast cancer diagnosis for BRCA1 and BRCA2 heterozygotes.
  • Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N,...Schmidt MK

  • Genet Med. 2021 Sep;23(9):1726-1737. doi: 10.1038/s41436-021-01198-7. Epub 2021 Jun 10.
Open Access button

2021-10-27

Figure 1. Four domains of research according to Patient-Centered Outcomes Research Institute.

Figure 1. Four domains of research according to Patient-Centered Outcomes Research Institute.
  • Cheung CK, Tucker-Seeley R, Davies S, Gilman M, Miller KA, Lopes G, Betz GD, Katerere-Virima T, Helbling LE, Thomas BN, Lewis MA

  • Future Oncol. 2021 Oct;17(28):3743-3756. doi: 10.2217/fon-2020-1213. Epub 2021 Jul 15.
Open Access button

2021-10-26

Visual Abstract.

Visual Abstract.
  • Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M

  • Blood Adv. 2021 Sep 28;5(18):3528-3539. doi: 10.1182/bloodadvances.2021004865.
Open Access button

2021-10-25

Figure 1. WBC count vs time (in months) with major events labeled.

Figure 1. WBC count vs time (in months) with major events labeled.
  • Chen JA, Hou Y, Roskin KM, Arber DA, Bangs CD, Baughn LB, Cherry AM, Ewalt MD, Fire AZ, Fresard L, Kearney HM, Montgomery SB, Ohgami RS, Pearce KE, Pitel BA, Merker JD, Gotlib J

  • Blood Adv. 2021 Sep 14;5(17):3492-3496. doi: 10.1182/bloodadvances.2020004174.
Open Access button

2021-10-22

Fig. 2: Building an integrative oncogene-dependency map of EGFRT790M/L858R, KRASG12V, and RIT1M90I

Fig. 2: Building an integrative oncogene-dependency map of EGFRT790M/L858R, KRASG12V, and RIT1M90I
  • Vichas A, Riley AK, Nkinsi NT, Kamlapurkar S, Parrish PCR, Lo A, Duke F, Chen J, Fung I, Watson J, Rees M, Gabel AM, Thomas JD, Bradley RK, Lee JK, Hatch EM, Baine MK, Rekhtman N, Ladanyi M, Piccioni F, Berger AH

  • Nat Commun. 2021 Aug 9;12(1):4789. doi: 10.1038/s41467-021-24841-y.
Open Access button

2021-10-21

Figure 2. Exon-exon junctions reads.

Figure 2. Exon-exon junctions reads.
  • Vural S, Chang LC, Yee LM, Sonkin D

  • Sci Rep. 2021 Aug 26;11(1):17275. doi: 10.1038/s41598-021-96700-1.
Open Access button

2021-10-20

Figure 3. OncoPrint plots of risk scores with mutational burden, sex, smoking status, asbestos exposure, histology, and mutation status for the top mutated genes.

Figure 3. OncoPrint plots of risk scores with mutational burden, sex, smoking status, asbestos exposure, histology, and mutation status for the top mutated genes.
  • Zauderer MG, Martin A, Egger J, Rizvi H, Offin M, Rimner A, Adusumilli PS, Rusch VW, Kris MG, Sauter JL, Ladanyi M, Shen R

  • Lancet Digit Health. 2021 Sep;3(9):e565-e576. doi: 10.1016/S2589-7500(21)00104-7. Epub 2021 Jul 28.
Open Access button

2021-10-19

Fig 1. 124I activity concentration in the phantom’s spheres as a function of increasing 131I activity in the background measured on the PET image reconstructed with the OSEM algorithm with 2 iterations and 16 subsets, TOF information and PSF modeling.

Fig 1. 124I activity concentration in the phantom’s spheres as a function of increasing 131I activity in the background measured on the PET image reconstructed with the OSEM algorithm with 2 iterations and 16 subsets, TOF information and PSF modeling.
  • Fanchon LM, Beattie BJ, Pentlow K, Larson SM, Humm JL

  • EJNMMI Phys. 2021 Jul 12;8(1):50. doi: 10.1186/s40658-021-00398-z.
Open Access button

2021-10-18

Fig 2. Immunotype classification significantly correlates with survival in ICB-treated patients with melanoma.

Fig 2. Immunotype classification significantly correlates with survival in ICB-treated patients with melanoma.
  • Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, Keegan N, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Chapman PB, Shoushtari AN, Betof AS, Momtaz P, Merghoub T, Wolchok JD, Panageas KS, Callahan MK

  • Sci Transl Med. 2021 Aug 25;13(608). pii: 13/608/eabf5107. doi: 10.1126/scitranslmed.abf5107.

2021-10-15

Figure 1. Intestinal homeostasis is tightly controlled by gut microbiota through a large number of microbial metabolites/components.

Figure 1. Intestinal homeostasis is tightly controlled by gut microbiota through a large number of microbial metabolites/components.
  • Tang M, Li S, Wei L, Hou Z, Qu J, Li L

  • Front Immunol. 2021 Sep 14;12:684605. doi: 10.3389/fimmu.2021.684605. eCollection 2021.
Open Access button

2021-10-14

Graphical abstract.

Graphical abstract.
  • Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F

  • Eur J Med Chem. 2021 Sep 4;226:113825. doi: 10.1016/j.ejmech.2021.113825.

2021-10-13

Figure. Overview of Data Sets and Studies.

Figure. Overview of Data Sets and Studies.
  • Daneshjou R, Smith MP, Sun MD, Rotemberg V, Zou J

  • JAMA Dermatol. 2021 Sep 22. pii: 2784295. doi: 10.1001/jamadermatol.2021.3129.

2021-10-12

Figure 2. Long-term United States and worldwide interest in search terms related to the diagnostic and therapeutic options of interventional radiology.

Figure 2. Long-term United States and worldwide interest in search terms related to the diagnostic and therapeutic options of interventional radiology.
  • Berning P, Maybody M, Deipolyi AR, Solomon SB, Dzaye O

  • J Vasc Interv Radiol. 2021 Oct;32(10):1445-1448.e1. doi: 10.1016/j.jvir.2021.07.005. Epub 2021 Jul 20.

2021-10-11

Fig 1 Adjusted overall survival for five years after landmark time points for first autologous haematopoietic cell transplantation in mantle cell lymphoma.

Fig 1 Adjusted overall survival for five years after landmark time points for first autologous haematopoietic cell transplantation in mantle cell lymphoma.
  • Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM

  • Br J Haematol. 2021 Sep 28. doi: 10.1111/bjh.17865.

2021-10-08

Figure 4: Sankey diagrams of patients with (A) prostate, (B) colorectal, (C) breast, (D) lung, (E) kidney and bladder, and (F) pancreatic primary cancers and their most common first and second sites of metastasis to nodal (in green) and nonnodal (bone: purple; liver: red; lung: blue; peritoneum: yellow; pleura: orange) organs.

Figure 4: Sankey diagrams of patients with (A) prostate, (B) colorectal, (C) breast, (D) lung, (E) kidney and bladder, and (F) pancreatic primary cancers and their most common first and second sites of metastasis to nodal (in green) and nonnodal (bone: purple; liver: red; lung: blue; peritoneum: yellow; pleura: orange) organs.
  • Do RKG, Lupton K, Causa Andrieu PI, Luthra A, Taya M, Batch K, Nguyen H, Rahurkar P, Gazit L, Nicholas K, Fong CJ, Gangai N, Schultz N, Zulkernine F, Sevilimedu V, Juluru K, Simpson A, Hricak H

  • Radiology. 2021 Oct;301(1):115-122. doi: 10.1148/radiol.2021210043. Epub 2021 Aug 3.

2021-10-07

Figure 5. Residues that interact with E2˜SUMO are mostly conserved between Siz2 and Siz1.

Figure 5. Residues that interact with E2˜SUMO are mostly conserved between Siz2 and Siz1.
  • Cappadocia L, Kochanczyk T, Lima CD

  • EMBO J. 2021 Sep 29:e103787. doi: 10.15252/embj.2019103787.

2021-10-06

Fig 1. Bladder cancer can be classified into various molecular subtypes based on gene expression profiling.

Fig 1. Bladder cancer can be classified into various molecular subtypes based on gene expression profiling.
  • Teo MY, Rosenberg JE

  • Clin Cancer Res. 2021 Sep 15;27(18):4950-4952. doi: 10.1158/1078-0432.CCR-21-1807. Epub 2021 Jul 19.

2021-10-05

Fig 1. The NXF1 mRNA export pathway. The major pathway for mRNA export from the nucleus to the cytoplasm in metazoans is regulated by a heterodimeric receptor composed of the proteins NXF1 bound to NXT1.

Fig 1. The NXF1 mRNA export pathway. The major pathway for mRNA export from the nucleus to the cytoplasm in metazoans is regulated by a heterodimeric receptor composed of the proteins NXF1 bound to NXT1.
  • Wang E, Abdel-Wahab O

  • Cancer Discov. 2021 Sep;11(9):2129-2131. doi: 10.1158/2159-8290.CD-21-0862.

2021-10-04

Fig. 1. Predicted probability of any moderate or greater toxicity over time during and after treatment based on treatment type.

Fig. 1. Predicted probability of any moderate or greater toxicity over time during and after treatment based on treatment type.
  • Lapen K, Sabol C, Tin AL, Lynch K, Kassa A, Mabli X, Ford J, Cha E, Bernstein MB, Braunstein LZ, Cahlon O, Daly BM, Sandler K, McCloskey SA, Vickers AJ, Khan AJ, Gillespie EF

  • Int J Radiat Oncol Biol Phys. 2021 Jul 24. pii: S0360-3016(21)02562-1. doi: 10.1016/j.ijrobp.2021.07.1692.

2021-10-01

Fig 1. Profiling single T cells in NSCLC treated with neoadjuvant PD-1 blockade.

Fig 1. Profiling single T cells in NSCLC treated with neoadjuvant PD-1 blockade.
  • Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, ... Smith KN

  • Nature. 2021 Aug;596(7870):126-132. doi: 10.1038/s41586-021-03752-4. Epub 2021 Jul 21.
Open Access button